Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence.

Published

Journal Article

PURPOSE: We developed an unbiased framework to study the association of several mutations in predicting resistance to hypomethylating agents (HMAs) in patients with myelodysplastic syndromes (MDS), analogous to consumer and commercial recommender systems in which customers who bought products A and B are likely to buy C: patients who have a mutation in gene A and gene B are likely to respond or not respond to HMAs. METHODS: We screened a cohort of 433 patients with MDS who received HMAs for the presence of common myeloid mutations in 29 genes that were obtained before the patients started therapy. The association between mutations and response was evaluated by the Apriori market basket analysis algorithm. Rules with the highest confidence (confidence that the association exists) and the highest lift (strength of the association) were chosen. We validated our biomarkers in samples from patients enrolled in the S1117 trial. RESULTS: Among 433 patients, 193 (45%) received azacitidine, 176 (40%) received decitabine, and 64 (15%) received HMA alone or in combination. The median age was 70 years (range, 31 to 100 years), and 28% were female. The median number of mutations per sample was three (range, zero to nine), and 176 patients (41%) had three or more mutations per sample. Association rules identified several genomic combinations as being highly associated with no response. These molecular signatures were present in 30% of patients with three or more mutations/sample with an accuracy rate of 87% in the training cohort and 93% in the validation cohort. CONCLUSION: Genomic biomarkers can identify, with high accuracy, approximately one third of patients with MDS who will not respond to HMAs. This study highlights the importance of machine learning technologies such as the recommender system algorithm in translating genomic data into useful clinical tools.

Full Text

Duke Authors

Cited Authors

  • Nazha, A; Sekeres, MA; Bejar, R; Rauh, MJ; Othus, M; Komrokji, RS; Barnard, J; Hilton, CB; Kerr, CM; Steensma, DP; DeZern, A; Roboz, G; Garcia-Manero, G; Erba, H; Ebert, BL; Maciejewski, JP

Published Date

  • 2019

Published In

Volume / Issue

  • 3 /

PubMed ID

  • 31663066

Pubmed Central ID

  • 31663066

International Standard Serial Number (ISSN)

  • 2473-4284

Digital Object Identifier (DOI)

  • 10.1200/po.19.00119

Language

  • eng

Conference Location

  • United States